Indaptus Therapeutics, Inc. (INDP) 10-Year Financial Performance & Capital Metrics

INDP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutIndaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$15M +6.2%
Net Income -$15M +2.6%
EPS (Diluted) -1.61 +12.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -187.52% -123.1%
ROIC -
Debt/Equity 0.02 +47.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 11.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-652.33%

ROCE

10Y Avg-76.26%

5Y Avg-85.83%

3Y Avg-109.74%

Latest-190.94%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	745.9K	701K	829K	859K	854K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-745.9K	-701K	-829K	-859K	-854K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.28%	0.06%	-0.18%	-0.04%	0.01%	1%	-	-	-	-
Operating Expenses+	6.85M	13.14M	28.61M	42.47M	34.09M	3.6M	7.73M	14.91M	16.38M	15.37M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.77M	3.07M	4.32M	7.07M	7.43M	944.25K	5.21M	8.59M	8.76M	8.11M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4.09M	10.07M	24.3M	35.4M	26.66M	2.66M	2.52M	6.32M	7.62M	7.25M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-7.6M	-13.85M	-29.44M	-43.33M	-34.95M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0%	-0.82%	-1.13%	-0.47%	0.19%	0.9%	-1.15%	-0.93%	-0.1%	0.06%
EBITDA+	-6.85M	-13.14M	-28.61M	-42.47M	-34.09M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.02%	-0.92%	-1.18%	-0.48%	0.2%	0.89%	-1.15%	-0.93%	-0.1%	0.06%
D&A (Non-Cash Add-back)	745.9K	701K	829K	859K	854K	852	1.4K	1.78K	1.28K	735
EBIT	-7.18M	-13.35M	-28.86M	-43.42M	-46.95M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
Net Interest Income+	0	160K	269K	829K	315K	0	17.72K	588.11K	0	0
Interest Income	44.78K	176K	286K	852K	330K	0	17.72K	588.11K	0	0
Interest Expense	0	16K	17K	23K	15K	0	0	0	0	0
Other Income/Expense	423.4K	484K	559K	-112K	-12.02M	15.11K	17.72K	588.11K	955K	343.72K
Pretax Income+	-7.18M	-13.36M	-28.88M	-43.44M	-46.96M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-4	0	29K	103K	638K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.01%	1%	1%	1%	1%	1%
Net Income+	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.26%	-0.86%	-1.16%	-0.51%	-0.09%	0.92%	-1.15%	-0.86%	-0.08%	0.03%
Net Income (Continuing)	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-73.70	-93.38	-130.96	-111.67	-112.74	-0.66	-1.89	-1.73	-1.84	-1.61
EPS Growth %	-37.99%	-0.27%	-0.4%	0.15%	-0.01%	0.99%	-1.86%	0.08%	-0.06%	0.13%
EPS (Basic)	-73.70	-93.38	-130.96	-111.67	-112.74	-0.66	-1.89	-1.73	-1.84	-1.61
Diluted Shares Outstanding	97.39K	143.1K	220.75K	389.91K	422.2K	5.41M	4.09M	8.26M	8.4M	9.36M
Basic Shares Outstanding	97.39K	143.1K	220.75K	389.91K	422.2K	5.41M	4.09M	8.26M	8.4M	9.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.19M	20.67M	56.34M	43.56M	13.74M	1.73M	40.39M	27.24M	14M	6.62M
Cash & Short-Term Investments	30.82M	18.29M	55.22M	40.58M	10.06M	1.64M	39.13M	26.43M	13.36M	5.79M
Cash Only	23.78M	16.44M	53.39M	39.25M	9.29M	1.64M	39.13M	9.63M	13.36M	5.79M
Short-Term Investments	7.04M	1.85M	1.82M	1.33M	770K	0	0	16.81M	0	0
Accounts Receivable	782.31K	721K	478K	2.03M	3.49M	0	21.06K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	83.55K	148.4K	0	0	0
Total Non-Current Assets+	4.09M	4.05M	8.21M	17.95M	7.54M	45.79K	189.37K	819.56K	928.67K	720.43K
Property, Plant & Equipment	4.09M	4.05M	8.21M	12.23M	3.82M	1.35K	172.89K	81.31K	173.94K	82.17K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	5.43M	3.72M	44.45K	16.48K	738.25K	754.73K	638.25K
Total Assets+	37.28M	24.72M	64.55M	61.51M	21.28M	1.78M	40.58M	28.06M	14.92M	7.34M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.98%	-0.34%	1.61%	-0.05%	-0.65%	-0.92%	21.82%	-0.31%	-0.47%	-0.51%
Total Current Liabilities+	1.32M	1.92M	5.75M	7.66M	8.34M	2.02M	4.6M	3.43M	2.77M	3.39M
Accounts Payable	615.26K	1.15M	1.85M	2.85M	3.51M	155.96K	2.64M	1.38M	806K	870.23K
Days Payables Outstanding	301.07	599.83	816.3	1.21K	1.5K	-	-	-	-	-
Short-Term Debt	0	0	0	0	544K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	701.87K	768K	3.89M	4.81M	2.86M	1.62M	498.73K	1.22M	1.21M	0
Current Ratio	25.20x	10.77x	9.80x	5.69x	1.65x	0.86x	8.77x	7.94x	5.05x	1.95x
Quick Ratio	25.20x	10.77x	9.80x	5.69x	1.65x	0.86x	8.77x	7.94x	5.05x	1.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	328.19K	97K	0	309K	1.4M	0	72.86K	0	73.35K	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	799K	0	72.86K	0	73.35K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	328.19K	97K	0	309K	604K	0	0	0	0	0
Total Liabilities	1.65M	2.02M	5.75M	7.96M	9.74M	2.02M	4.68M	3.43M	2.85M	3.39M
Total Debt+	0	0	0	0	1.34M	0	169.33K	80.49K	175.05K	84.16K
Net Debt	-23.78M	-16.44M	-53.39M	-39.25M	-7.95M	-1.64M	-38.96M	-9.55M	-13.19M	-5.7M
Debt / Equity	-	-	-	-	0.12x	-	0.00x	0.00x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-865.38x	-1731.71x	-1883.83x	-2329.73x	-	-	-	-	-
Total Equity+	35.63M	22.7M	58.8M	53.55M	11.54M	-237.7K	35.9M	24.63M	12.08M	3.94M
Equity Growth %	2.76%	-0.36%	1.59%	-0.09%	-0.78%	-1.02%	152.03%	-0.31%	-0.51%	-0.67%
Book Value per Share	365.86	158.66	266.37	137.33	27.32	-0.04	8.78	2.98	1.44	0.42
Total Shareholders' Equity	35.63M	22.7M	58.8M	53.55M	11.54M	-237.7K	35.9M	24.63M	12.08M	3.94M
Common Stock	694.16K	727K	727K	727K	727K	19.45K	82.59K	84.01K	84.01K	120.14K
Retained Earnings	-49.61M	-62.63M	-98.28M	-141.82M	-189.42M	-7.96M	-15.67M	-29.99M	-45.42M	-60.44M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-378K	-378K	0	0	0	0	96.43K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.93M	-12.01M	-22.13M	-39.08M	-29.05M	-3.32M	-11.29M	-13.08M	-13.41M	-12.32M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.67%	-0.51%	-0.84%	-0.77%	0.26%	0.89%	-2.4%	-0.16%	-0.03%	0.08%
Net Income	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Depreciation & Amortization	745.9K	701K	829K	859K	854K	852	1.4K	1.78K	1.28K	735
Stock-Based Compensation	0	0	0	0	0	139.96K	1.51M	2.96M	2.97M	2.31M
Deferred Taxes	0	0	0	0	281K	0	-5.75M	0	0	0
Other Non-Cash Items	3.75M	1.69M	-2.57M	6.64M	17.19M	0	5.75M	-134.16K	-430.99K	0
Working Capital Changes	-1.67M	392K	5.09M	-642K	227K	118.71K	-5.09M	-1.58M	-518.07K	392.25K
Change in Receivables	-2.08M	-23K	1.26M	-1.86M	-747K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	3.83M	1.19M	679K	113.9K	-4.24M	-1.15M	-680.52K	474.06K
Cash from Investing+	-6.39M	4.72M	-4.75M	-9.3M	-3.21M	0	447.75K	-16.43M	17.14M	0
Capital Expenditures	-1.39M	-482K	-5M	-9.6M	-921K	0	-3.85K	-172.56K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-2.87M	0	0	172.56K	0	0
Cash from Financing+	31.94M	0	63.71M	35.06M	2.37M	1.16M	48.34M	0	0	4.75M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	43.34M	0	0	-762.7K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.32M	-12.49M	-27.13M	-48.67M	-29.97M	-3.32M	-11.29M	-13.25M	-13.41M	-12.32M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.93%	-0.34%	-1.17%	-0.79%	0.38%	0.89%	-2.4%	-0.17%	-0.01%	0.08%
FCF per Share	-95.68	-87.26	-122.91	-124.84	-70.98	-0.61	-2.76	-1.60	-1.60	-1.32
FCF Conversion (FCF/Net Income)	1.10x	0.90x	0.77x	0.90x	0.61x	0.93x	1.46x	0.91x	0.87x	0.82x
Interest Paid	0	0	0	0	0	14.26K	0	0	0	0
Taxes Paid	0	0	0	0	0	800	800	2.4K	1.6K	1.6K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.82%	-45.81%	-70.94%	-77.52%	-146.28%	-63.45%	-43.25%	-47.32%	-84.04%	-187.52%
Return on Invested Capital (ROIC)	-73.43%	-114.62%	-378.23%	-329.77%	-293.09%	-315.58%	-	-186.06%	-175.81%	-
Debt / Equity	-	-	-	-	0.12x	-	0.00x	0.00x	0.01x	0.02x
Interest Coverage	-	-865.38x	-1731.71x	-1883.83x	-2329.73x	-	-	-	-	-
FCF Conversion	1.10x	0.90x	0.77x	0.90x	0.61x	0.93x	1.46x	0.91x	0.87x	0.82x

Frequently Asked Questions

Growth & Financials

Indaptus Therapeutics, Inc. (INDP) grew revenue by 0.0% over the past year. Growth has been modest.

Indaptus Therapeutics, Inc. (INDP) reported a net loss of $16.9M for fiscal year 2024.

Dividend & Returns

Indaptus Therapeutics, Inc. (INDP) has a return on equity (ROE) of -187.5%. Negative ROE indicates the company is unprofitable.

Indaptus Therapeutics, Inc. (INDP) had negative free cash flow of $15.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Indaptus Therapeutics, Inc. (INDP) 10-Year Financial Performance & Capital Metrics

INDP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$15M +6.2%
Net Income -$15M +2.6%
EPS (Diluted) -1.61 +12.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -187.52% -123.1%
ROIC -
Debt/Equity 0.02 +47.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 11.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-652.33%

ROCE

10Y Avg-76.26%

5Y Avg-85.83%

3Y Avg-109.74%

Latest-190.94%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	745.9K	701K	829K	859K	854K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-745.9K	-701K	-829K	-859K	-854K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.28%	0.06%	-0.18%	-0.04%	0.01%	1%	-	-	-	-
Operating Expenses+	6.85M	13.14M	28.61M	42.47M	34.09M	3.6M	7.73M	14.91M	16.38M	15.37M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.77M	3.07M	4.32M	7.07M	7.43M	944.25K	5.21M	8.59M	8.76M	8.11M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4.09M	10.07M	24.3M	35.4M	26.66M	2.66M	2.52M	6.32M	7.62M	7.25M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-7.6M	-13.85M	-29.44M	-43.33M	-34.95M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0%	-0.82%	-1.13%	-0.47%	0.19%	0.9%	-1.15%	-0.93%	-0.1%	0.06%
EBITDA+	-6.85M	-13.14M	-28.61M	-42.47M	-34.09M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.02%	-0.92%	-1.18%	-0.48%	0.2%	0.89%	-1.15%	-0.93%	-0.1%	0.06%
D&A (Non-Cash Add-back)	745.9K	701K	829K	859K	854K	852	1.4K	1.78K	1.28K	735
EBIT	-7.18M	-13.35M	-28.86M	-43.42M	-46.95M	-3.6M	-7.73M	-14.91M	-16.38M	-15.37M
Net Interest Income+	0	160K	269K	829K	315K	0	17.72K	588.11K	0	0
Interest Income	44.78K	176K	286K	852K	330K	0	17.72K	588.11K	0	0
Interest Expense	0	16K	17K	23K	15K	0	0	0	0	0
Other Income/Expense	423.4K	484K	559K	-112K	-12.02M	15.11K	17.72K	588.11K	955K	343.72K
Pretax Income+	-7.18M	-13.36M	-28.88M	-43.44M	-46.96M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-4	0	29K	103K	638K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.01%	1%	1%	1%	1%	1%
Net Income+	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.26%	-0.86%	-1.16%	-0.51%	-0.09%	0.92%	-1.15%	-0.86%	-0.08%	0.03%
Net Income (Continuing)	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-73.70	-93.38	-130.96	-111.67	-112.74	-0.66	-1.89	-1.73	-1.84	-1.61
EPS Growth %	-37.99%	-0.27%	-0.4%	0.15%	-0.01%	0.99%	-1.86%	0.08%	-0.06%	0.13%
EPS (Basic)	-73.70	-93.38	-130.96	-111.67	-112.74	-0.66	-1.89	-1.73	-1.84	-1.61
Diluted Shares Outstanding	97.39K	143.1K	220.75K	389.91K	422.2K	5.41M	4.09M	8.26M	8.4M	9.36M
Basic Shares Outstanding	97.39K	143.1K	220.75K	389.91K	422.2K	5.41M	4.09M	8.26M	8.4M	9.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.19M	20.67M	56.34M	43.56M	13.74M	1.73M	40.39M	27.24M	14M	6.62M
Cash & Short-Term Investments	30.82M	18.29M	55.22M	40.58M	10.06M	1.64M	39.13M	26.43M	13.36M	5.79M
Cash Only	23.78M	16.44M	53.39M	39.25M	9.29M	1.64M	39.13M	9.63M	13.36M	5.79M
Short-Term Investments	7.04M	1.85M	1.82M	1.33M	770K	0	0	16.81M	0	0
Accounts Receivable	782.31K	721K	478K	2.03M	3.49M	0	21.06K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	83.55K	148.4K	0	0	0
Total Non-Current Assets+	4.09M	4.05M	8.21M	17.95M	7.54M	45.79K	189.37K	819.56K	928.67K	720.43K
Property, Plant & Equipment	4.09M	4.05M	8.21M	12.23M	3.82M	1.35K	172.89K	81.31K	173.94K	82.17K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	5.43M	3.72M	44.45K	16.48K	738.25K	754.73K	638.25K
Total Assets+	37.28M	24.72M	64.55M	61.51M	21.28M	1.78M	40.58M	28.06M	14.92M	7.34M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.98%	-0.34%	1.61%	-0.05%	-0.65%	-0.92%	21.82%	-0.31%	-0.47%	-0.51%
Total Current Liabilities+	1.32M	1.92M	5.75M	7.66M	8.34M	2.02M	4.6M	3.43M	2.77M	3.39M
Accounts Payable	615.26K	1.15M	1.85M	2.85M	3.51M	155.96K	2.64M	1.38M	806K	870.23K
Days Payables Outstanding	301.07	599.83	816.3	1.21K	1.5K	-	-	-	-	-
Short-Term Debt	0	0	0	0	544K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	701.87K	768K	3.89M	4.81M	2.86M	1.62M	498.73K	1.22M	1.21M	0
Current Ratio	25.20x	10.77x	9.80x	5.69x	1.65x	0.86x	8.77x	7.94x	5.05x	1.95x
Quick Ratio	25.20x	10.77x	9.80x	5.69x	1.65x	0.86x	8.77x	7.94x	5.05x	1.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	328.19K	97K	0	309K	1.4M	0	72.86K	0	73.35K	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	799K	0	72.86K	0	73.35K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	328.19K	97K	0	309K	604K	0	0	0	0	0
Total Liabilities	1.65M	2.02M	5.75M	7.96M	9.74M	2.02M	4.68M	3.43M	2.85M	3.39M
Total Debt+	0	0	0	0	1.34M	0	169.33K	80.49K	175.05K	84.16K
Net Debt	-23.78M	-16.44M	-53.39M	-39.25M	-7.95M	-1.64M	-38.96M	-9.55M	-13.19M	-5.7M
Debt / Equity	-	-	-	-	0.12x	-	0.00x	0.00x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-865.38x	-1731.71x	-1883.83x	-2329.73x	-	-	-	-	-
Total Equity+	35.63M	22.7M	58.8M	53.55M	11.54M	-237.7K	35.9M	24.63M	12.08M	3.94M
Equity Growth %	2.76%	-0.36%	1.59%	-0.09%	-0.78%	-1.02%	152.03%	-0.31%	-0.51%	-0.67%
Book Value per Share	365.86	158.66	266.37	137.33	27.32	-0.04	8.78	2.98	1.44	0.42
Total Shareholders' Equity	35.63M	22.7M	58.8M	53.55M	11.54M	-237.7K	35.9M	24.63M	12.08M	3.94M
Common Stock	694.16K	727K	727K	727K	727K	19.45K	82.59K	84.01K	84.01K	120.14K
Retained Earnings	-49.61M	-62.63M	-98.28M	-141.82M	-189.42M	-7.96M	-15.67M	-29.99M	-45.42M	-60.44M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-378K	-378K	0	0	0	0	96.43K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.93M	-12.01M	-22.13M	-39.08M	-29.05M	-3.32M	-11.29M	-13.08M	-13.41M	-12.32M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.67%	-0.51%	-0.84%	-0.77%	0.26%	0.89%	-2.4%	-0.16%	-0.03%	0.08%
Net Income	-7.18M	-13.36M	-28.91M	-43.54M	-47.6M	-3.58M	-7.71M	-14.32M	-15.42M	-15.02M
Depreciation & Amortization	745.9K	701K	829K	859K	854K	852	1.4K	1.78K	1.28K	735
Stock-Based Compensation	0	0	0	0	0	139.96K	1.51M	2.96M	2.97M	2.31M
Deferred Taxes	0	0	0	0	281K	0	-5.75M	0	0	0
Other Non-Cash Items	3.75M	1.69M	-2.57M	6.64M	17.19M	0	5.75M	-134.16K	-430.99K	0
Working Capital Changes	-1.67M	392K	5.09M	-642K	227K	118.71K	-5.09M	-1.58M	-518.07K	392.25K
Change in Receivables	-2.08M	-23K	1.26M	-1.86M	-747K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	3.83M	1.19M	679K	113.9K	-4.24M	-1.15M	-680.52K	474.06K
Cash from Investing+	-6.39M	4.72M	-4.75M	-9.3M	-3.21M	0	447.75K	-16.43M	17.14M	0
Capital Expenditures	-1.39M	-482K	-5M	-9.6M	-921K	0	-3.85K	-172.56K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-2.87M	0	0	172.56K	0	0
Cash from Financing+	31.94M	0	63.71M	35.06M	2.37M	1.16M	48.34M	0	0	4.75M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	43.34M	0	0	-762.7K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.32M	-12.49M	-27.13M	-48.67M	-29.97M	-3.32M	-11.29M	-13.25M	-13.41M	-12.32M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.93%	-0.34%	-1.17%	-0.79%	0.38%	0.89%	-2.4%	-0.17%	-0.01%	0.08%
FCF per Share	-95.68	-87.26	-122.91	-124.84	-70.98	-0.61	-2.76	-1.60	-1.60	-1.32
FCF Conversion (FCF/Net Income)	1.10x	0.90x	0.77x	0.90x	0.61x	0.93x	1.46x	0.91x	0.87x	0.82x
Interest Paid	0	0	0	0	0	14.26K	0	0	0	0
Taxes Paid	0	0	0	0	0	800	800	2.4K	1.6K	1.6K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.82%	-45.81%	-70.94%	-77.52%	-146.28%	-63.45%	-43.25%	-47.32%	-84.04%	-187.52%
Return on Invested Capital (ROIC)	-73.43%	-114.62%	-378.23%	-329.77%	-293.09%	-315.58%	-	-186.06%	-175.81%	-
Debt / Equity	-	-	-	-	0.12x	-	0.00x	0.00x	0.01x	0.02x
Interest Coverage	-	-865.38x	-1731.71x	-1883.83x	-2329.73x	-	-	-	-	-
FCF Conversion	1.10x	0.90x	0.77x	0.90x	0.61x	0.93x	1.46x	0.91x	0.87x	0.82x

Frequently Asked Questions

Growth & Financials

Indaptus Therapeutics, Inc. (INDP) grew revenue by 0.0% over the past year. Growth has been modest.

Indaptus Therapeutics, Inc. (INDP) reported a net loss of $16.9M for fiscal year 2024.

Dividend & Returns

Indaptus Therapeutics, Inc. (INDP) has a return on equity (ROE) of -187.5%. Negative ROE indicates the company is unprofitable.

Indaptus Therapeutics, Inc. (INDP) had negative free cash flow of $15.5M in fiscal year 2024, likely due to heavy capital investments.